PTEN and neoplasm: A recent preclinical study evaluated the effect of AZD8186, a selective PI3Kβ/δ inhibitor, on mice injected with PTEN-deficient TNBC tumors, but demonstrated mediocre anti-tumor effect as a single agent or combined with paclitaxel (Owusu-Brackett et al., 2020).